A case of severe cutaneous adverse reaction following administration of the Janssen Ad26.COV2.S COVID-19 vaccine
Kristen Lospinoso, Cameron Nichols, Stephen J. Malachowski, Mark C. Mochel, Fnu Nutan
Abstract
On 21 January 2021, an interim analysis of a phase-3 clinical trial revealed that the investigational, recombinant-vector COVID-19 vaccine developed by Janssen Pharmaceuticals, Janssen Ad26.COV2.S, was both effective and safe in preventing moderate and severe COVID-19 in adults.1 The vaccine was approved in late February 2021 by the Food and Drug Administration, following Pfizer's BNT162b2 and Moderna's messenger RNA-1273 approval in in December 2020. All 3 vaccines are considered safe by clinical trials.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)Food and drug administrationClinical trialAdverse effectSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)InterimInterim analysis2019-20 coronavirus outbreakPharmacologyVirologyInternal medicineOutbreakHistoryArchaeologyInfectious disease (medical specialty)DiseaseDrug-Induced Adverse ReactionsAutoimmune Bullous Skin DiseasesHeparin-Induced Thrombocytopenia and Thrombosis